Full-Time
Engineer – AI Developer Platforms
Updated on 8/12/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
Compensation Overview
CA$95.9k - CA$129.8k/yr
Remote in Canada
Remote
Bachelor's, Master's
 Software Engineering (1) |
|---|
Get referred to Amgen
See people who can refer or advise you
- A Master's degree in Computer Science, Information Technology, Engineering, or a related field, or a Bachelor's degree with at least 3 years of relevant experience in those fields.
- Relevant certifications in cloud platforms, software development, cybersecurity, developer tools, or generative artificial intelligence are a plus.
- Hands-on experience writing code in at least one modern programming language, such as Java or JavaScript/TypeScript.
- A foundation in debugging, source control, automated testing, and code review.
- Experience with, or strong interest in, AI coding assistants and a willingness to learn how to verify and improve generated output.
- Ability to learn unfamiliar codebases, follow established engineering standards, and document work clearly.
- Use AI coding tools in representative codebases to understand code, implement small changes, debug issues, create tests, and improve documentation.
- Contribute to structured evaluations of AI coding tools across common engineering workflows, documenting observations, results, and limitations.
- Build small prototypes, scripts, or reference examples that demonstrate practical AI-assisted development workflows.
- Validate AI-assisted output using tests, code review, and established engineering practices, and raise quality, security, data-handling, or reliability concerns with the team.
- Work with engineers, product partners, and platform teams to gather feedback and improve developer workflows.
- Help maintain reusable prompts, repository guidance, workflow templates, and onboarding materials, and share practical learnings with the team.
- Support and deliver practical training and enablement sessions for development teams on approved AI-enabled development practices, including effective prompting, code validation, testing, secure use, and human review.
- Experience with OpenAI Codex, Claude Code, or comparable AI-assisted development tools.
- Exposure to cloud, developer tooling, internal platform, or automation projects.
- Familiarity with secure development, regulated environments, or responsible artificial intelligence practices.
- Experience in biotechnology, pharmaceuticals, healthcare, or another regulated industry.
- Strong analytical, troubleshooting, and attention-to-detail skills.
- Clear written and verbal communication skills.
- Curiosity, initiative, and willingness to learn emerging technologies quickly.
- Organized, collaborative approach to managing priorities and working with global, virtual teams.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $10.05 billion, and guidance rose to $38.2-$39.4 billion.
- Repatha sales jumped 37% in Q2 2026; Uplizna climbed 90%.
- MariTide Phase 3 programs are enrolling now, with obesity readouts expected in 2027.
What critics are saying
- FDA proposed Tavneos withdrawal on April 27, 2026 after data-integrity findings.
- July 2026 Amgen settled a $74 million IRS-disclosure suit; tax litigation continues.
- July 2026 layoffs hit Amgen again, signaling operating strain and portfolio pruning.
What makes Amgen unique
- Repatha, Uplizna, and Imdelltra diversified Amgen beyond Enbrel and Prolia.
- MariTide’s quarterly-or-sparser dosing targets obesity with lower treatment burden than weekly injectables.
- Amgen’s 2025-2026 launches span cardiology, oncology, and rare disease globally.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.
Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.
Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.
Amgen secured a preliminary injunction in early June 2026 blocking Colorado's proposed 70% price cap on Enbrel, its rheumatoid arthritis drug. The federal judge's decision preserves pricing flexibility for the legacy asset. However, the company initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the US due to foreign substances and manufacturing deviations. While not yet financially material, the recalls highlight ongoing operational risks. Amgen's investment case depends on its diversified portfolio offsetting pricing pressure and biosimilar competition. The company projects revenue of $40.1 billion and earnings of $9.9 billion by 2029, requiring 2.5% annual revenue growth. Current 2026 guidance stands at $37.1–$38.5 billion in revenue. The combination of pricing relief and quality concerns presents investors with a rebalanced risk-reward profile for the biotech company.
The New England Journal of Medicine has retracted the 2021 clinical trial that supported approval of Amgen's Tavneos, a treatment for ANCA-associated vasculitis that generated $459 million in sales last year. The retraction followed an FDA investigation revealing that results from nine patients were altered after the study database was finalised, whilst some researchers had been unblinded. The FDA alleges the original data showed no statistically significant difference between Tavneos and existing treatments, but subsequent changes made the drug appear more effective. The agency proposed withdrawing Tavneos from the US market in April, whilst European regulators have also recommended removal. Amgen, which acquired ChemoCentryx for $3.7 billion in 2022, continues selling Tavneos and has requested an FDA hearing. The company says it is engaging independent researchers to reanalyse the data.